Boehringer-Ingelheim's U.S. process and product patents (nos. 3202660 and 3236857, respectively) for the antihypertensive agent clonidine have expired; however, composition/use patent no. 3454701, issued in 1969, will be in effect until July 8, 1986. "The Pink Sheet" incorrectly included Catapres among a list of post-1962 drugs that will be accessible to ANDA competition by Jan. 1, 1985 (Oct. 29, p. 13)
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.